[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.202.44. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Association of Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer

Educational Objective To review If there is a difference in quality of life and psychosocial outcomes between marijuana users and nonusers who have newly diagnosed head and neck cancer.
1 Credit CME
Key Points

Question  Is there a difference in quality of life and psychosocial outcomes between marijuana users and nonusers who have newly diagnosed head and neck cancer?

Findings  In this case-matched cohort study, 74 patients with newly diagnosed head and neck cancer who were marijuana users appeared to have quality of life differences compared with 74 who did not use marijuana, including decreased anxiety, pain, and depression and increased appetite and generalized feelings of well-being on the Edmonton Symptom Assessment System and the EuroQol-5D questionnaires.

Meaning  Recreational marijuana use potentially improves quality of life and psychosocial symptoms among patients with newly diagnosed head and neck cancer.

Abstract

Importance  Cannabis sativa, the most widely used illicit substance in Canada, has a unique ability to facilitate relaxation and relieve anxiety while reducing pain. However, no study to date has examined quality of life (QOL) and psychosocial issues in relation to the use of this drug among patients with newly diagnosed head and neck cancer (HNC).

Objective  To examine the differences in QOL and psychosocial outcomes between marijuana users and nonusers with newly diagnosed HNC.

Design, Setting, and Participants  This prospective cohort study was conducted at a tertiary care cancer center. Patients were enrolled consecutively and prospectively at the time of HNC diagnosis from January 1, 2011, to January 1, 2015. Seventy-four patients who were current marijuana users were case matched to 74 nonusers in a 1:1 scheme based on age, sex, and tumor subsite. All patient demographic and QOL data were collected prospectively, and data analysis was conducted from November 1 to December 1, 2017.

Main Outcomes and Measure  The QOL outcome was assessed using the EuroQol-5D (EQ5D) and the Edmonton Symptom Assessment System (ESAS) questionnaires.

Results  A total of 148 patients were included in this study: 74 in the marijuana user group (mean [SD] age, 62.3 [10.3] years; male sex, 61 patients [82%]) and 74 in the marijuana nonuser group (mean age, 62.2 years; male sex, 63 patients [85%]). There was no statistically significant difference in age, sex, tumor subsite, clinical TNM staging, treatment modality, or mean Karnofsky score between the 2 groups. On univariate analysis, there was no statistically significant difference in the mobility, self-care, and usual activities domains of the EQ5D. Marijuana users had significantly lower scores in the anxiety/depression (difference, 0.74; 95% CI, 0.557-0.930) and pain/discomfort (difference, 0.29; 95% CI, 0.037-1.541) domains. Wilcoxon rank sum test confirmed the results of the EQ5D with improvements in the pain/discomfort (z score, −2.60) and anxiety/depression (z score, −6.71) domains. Marijuana users had less pain, were less tired, were less depressed, were less anxious, had more appetite, were less drowsy, and had better general well-being according to the ESAS. A Wilcoxon rank sum test confirmed a statistically significant improvement in ESAS scores within the domains of anxiety (z score, −10.04), pain (z score, −2.36), tiredness (z score, −5.02), depression (z score, −5.96), drowsiness (z score, −5.51), appetite (z score, −4.17), and general well-being (z score, −4.43).

Conclusions and Relevance  This prospective case-matched study suggests that there may be significant QOL benefits, including decreased anxiety, pain, and depression and increased appetite and generalized feelings of well-being, associated with marijuana use among patients with newly diagnosed HNC.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: March 31, 2018.

Corresponding Author: Michael K. Gupta, MD, MSc, FRCSC, St Joseph’s Healthcare Hamilton, G836, 50 Charlton Ave E, Hamilton, ON L8N4A6, Canada (michaelkgupta@hotmail.com).

Published Online: August 2, 2018. doi:10.1001/jamaoto.2018.0486

Author Contributions: Dr Gupta had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Zhang, Archibald, Gupta.

Acquisition, analysis, or interpretation of data: Zhang, Xie, Jackson, Gupta.

Drafting of the manuscript: Zhang, Xie, Gupta.

Critical revision of the manuscript for important intellectual content: Zhang, Archibald, Jackson, Gupta.

Statistical analysis: Zhang, Gupta.

Obtained funding: Zhang.

Administrative, technical, or material support: Zhang, Jackson, Gupta.

Study supervision: Zhang, Archibald, Gupta.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Meeting Presentation: This study was presented at the AHNS 2018 Annual Meeting; April 18, 2018; National Harbor, Maryland.

References
1.
Carlson  LE, Waller  A, Mitchell  AJ.  Screening for distress and unmet needs in patients with cancer: review and recommendations.  J Clin Oncol. 2012;30(11):1160-1177. doi:10.1200/JCO.2011.39.5509PubMedGoogle ScholarCrossref
2.
Chen  AM, Jennelle  RL, Grady  V,  et al.  Prospective study of psychosocial distress among patients undergoing radiotherapy for head and neck cancer.  Int J Radiat Oncol Biol Phys. 2009;73(1):187-193. doi:10.1016/j.ijrobp.2008.04.010PubMedGoogle ScholarCrossref
3.
Zabora  J, BrintzenhofeSzoc  K, Curbow  B, Hooker  C, Piantadosi  S.  The prevalence of psychological distress by cancer site.  Psychooncology. 2001;10(1):19-28. doi:10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6PubMedGoogle ScholarCrossref
4.
Williams  C.  Psychosocial distress and distress screening in multidisciplinary head and neck cancer treatment.  Otolaryngol Clin North Am. 2017;50(4):807-823. doi:10.1016/j.otc.2017.04.002PubMedGoogle ScholarCrossref
5.
Cancer ACoSCo.  Cancer Program Standards 2012 Edition Version 1.2.1: Ensuring Patient-Centered Care. Chicago, IL: American College of Surgeons; 2012.
6.
Holland  JC, Andersen  B, Breitbart  WS,  et al.  Distress management.  J Natl Compr Canc Netw. 2013;11(2):190-209. doi:10.6004/jnccn.2013.0027PubMedGoogle ScholarCrossref
7.
Rotermann  M, Langlois  K.  Prevalence and correlates of marijuana use in Canada, 2012.  Health Rep. 2015;26(4):10-15.PubMedGoogle Scholar
8.
Greer  GR, Grob  CS, Halberstadt  AL.  PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.  J Psychoactive Drugs. 2014;46(1):73-77. doi:10.1080/02791072.2013.873843PubMedGoogle ScholarCrossref
9.
Johnson  MJ, Pierce  JD, Mavandadi  S,  et al.  Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD.  J Affect Disord. 2016;190:439-442. doi:10.1016/j.jad.2015.10.048PubMedGoogle ScholarCrossref
10.
Kramer  JL.  Medical marijuana for cancer.  CA Cancer J Clin. 2015;65(2):109-122. doi:10.3322/caac.21260PubMedGoogle ScholarCrossref
11.
Nugent  SM, Morasco  BJ, O’Neil  ME,  et al.  The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review.  Ann Intern Med. 2017;167(5):319-331. doi:10.7326/M17-0155PubMedGoogle ScholarCrossref
12.
Karnofsky  DA, Burchenal  JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed.  Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:199-205.
13.
Statistics Canada. Your guide to statistical information from the 2011 Census of Population Program. https://www12.statcan.gc.ca/census-recensement/2011/dp-pd/index-eng.cfm. Updated February 20, 2017. Accessed June 8, 2018.
14.
Bruera  E, Kuehn  N, Miller  MJ, Selmser  P, Macmillan  K.  The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.  J Palliat Care. 1991;7(2):6-9.PubMedGoogle Scholar
15.
Hurst  NP, Kind  P, Ruta  D, Hunter  M, Stubbings  A.  Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).  Br J Rheumatol. 1997;36(5):551-559. doi:10.1093/rheumatology/36.5.551PubMedGoogle ScholarCrossref
16.
Blanco  C, Hasin  DS, Wall  MM,  et al.  Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study.  JAMA Psychiatry. 2016;73(4):388-395. doi:10.1001/jamapsychiatry.2015.3229PubMedGoogle ScholarCrossref
17.
Bronner  MB, Nguyen  MH, Smets  EMA, van de Ven  AWH, van Weert  JCM.  Anxiety during cancer diagnosis: examining the influence of monitoring coping style and treatment plan.  Psychooncology. 2018:27(2):661-667. doi:10.1002/pon.4560PubMedGoogle ScholarCrossref
18.
Elliott  DA, Nabavizadeh  N, Romer  JL, Chen  Y, Holland  JM.  Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy.  Support Care Cancer. 2016;24(8):3517-3524. doi:10.1007/s00520-016-3180-8PubMedGoogle ScholarCrossref
19.
Ko  GD, Bober  SL, Mindra  S, Moreau  JM.  Medical cannabis: the Canadian perspective.  J Pain Res. 2016;9:735-744. doi:10.2147/JPR.S98182PubMedGoogle ScholarCrossref
20.
Romero-Sandoval  EA, Kolano  AL, Alvarado-Vázquez  PA.  Cannabis and cannabinoids for chronic pain.  Curr Rheumatol Rep. 2017;19(11):67. doi:10.1007/s11926-017-0693-1PubMedGoogle ScholarCrossref
21.
Steenkamp  MM, Blessing  EM, Galatzer-Levy  IR, Hollahan  LC, Anderson  WT.  Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review.  Depress Anxiety. 2017;34(3):207-216. doi:10.1002/da.22596PubMedGoogle ScholarCrossref
22.
Hoffmann  DE, Weber  E.  Medical marijuana and the law.  N Engl J Med. 2010;362(16):1453-1457. doi:10.1056/NEJMp1000695PubMedGoogle ScholarCrossref
23.
Ligresti  A, De Petrocellis  L, Di Marzo  V.  From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology.  Physiol Rev. 2016;96(4):1593-1659. doi:10.1152/physrev.00002.2016PubMedGoogle ScholarCrossref
24.
Passie  T, Emrich  HM, Karst  M, Brandt  SD, Halpern  JH.  Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence.  Drug Test Anal. 2012;4(7-8):649-659. doi:10.1002/dta.1377PubMedGoogle ScholarCrossref
25.
Himmi  T, Dallaporta  M, Perrin  J, Orsini  JC.  Neuronal responses to Δ9-tetrahydrocannabinol in the solitary tract nucleus.  Eur J Pharmacol. 1996;312(3):273-279. doi:10.1016/0014-2999(96)00490-6PubMedGoogle ScholarCrossref
26.
Tramèr  MR, Carroll  D, Campbell  FA, Reynolds  DJ, Moore  RA, McQuay  HJ.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.  BMJ. 2001;323(7303):16-21. doi:10.1136/bmj.323.7303.16PubMedGoogle ScholarCrossref
27.
Parker  LA, Kwiatkowska  M, Mechoulam  R.  Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting.  Physiol Behav. 2006;87(1):66-71. doi:10.1016/j.physbeh.2005.08.045PubMedGoogle ScholarCrossref
28.
Noyes  R  Jr, Brunk  SF, Baram  DA, Canter  A.  Analgesic effect of delta-9-tetrahydrocannabinol.  J Clin Pharmacol. 1975;15(2-3):139-143. doi:10.1002/j.1552-4604.1975.tb02348.xPubMedGoogle ScholarCrossref
29.
Johnson  JR, Burnell-Nugent  M, Lossignol  D, Ganae-Motan  ED, Potts  R, Fallon  MT.  Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.  J Pain Symptom Manage. 2010;39(2):167-179. doi:10.1016/j.jpainsymman.2009.06.008PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close